Barclays
MBRX icon

Barclays’s Moleculin Biotech MBRX Stock Holding History

Barclays’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14
Closed -$335 – 5429
2025
Q1 		$335 Buy
+14
New +$470 ﹤0.01% 5105
2021
Q1 		– Sell
-3
Closed -$5K – 4999
2020
Q4 		$5K Sell
3
-3
-50% -$5.32K ﹤0.01% 4782
2020
Q3 		$10K Buy
6
+5
+500% +$10.6K ﹤0.01% 5010
2020
Q2 		$1K Buy
+1
New +$2.37K ﹤0.01% 5474
2016
Q3 		– Sell
-1
Closed -$9K – 6717
2016
Q2 		$9K Buy
+1
New +$16.2K ﹤0.01% 5577

Other funds holding MBRX

Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays's MBRX Position: Q2 2025 in Review

Barclays sold out of Moleculin Biotech (MBRX) in Q2 2025, closing a stake of 14 shares — an estimated $335 sold.

Barclays first reported a position in MBRX in Q2 2016 and held it in 5 quarters. The position peaked at $10K in Q3 2020. 21 funds tracked by Wall St. Rank hold MBRX as of Q2 2025.

  • Barclays reported no remaining Moleculin Biotech position as of Q2 2025 after selling out during the quarter.
  • Barclays sold 14 Moleculin Biotech shares in Q2 2025, an estimated $335.
  • Barclays first reported a position in Moleculin Biotech in Q2 2016 and held it in 5 quarters.
  • Barclays's Moleculin Biotech position peaked at $10K in Q3 2020.
  • 21 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.